Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Moderna (MRNA) Stock Price & Analysis
14,929 Followers
MRNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.55 - $144.93
Previous Close$103.79
Volume887.48K
Average Volume (3M)3.84M
Market Cap
$39.76B
Enterprise Value$32.38B
Total Cash (Recent Filing)$8.60B
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)-8.4
Beta1.10
Next Earnings
May 02, 2024EPS Estimate
-$3.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.40
Shares Outstanding382,073,208
10 Day Avg. Volume3,499,047
30 Day Avg. Volume3,835,210
Standard Deviation0.26
R-Squared0.11
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.88
Price to Sales (P/S)5.79
Price to Cash Flow (P/CF)16.00
P/FCF Ratio22.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit15.03
Enterprise Value/Ebitda-9.86
Forecast
1Y Price Target
$122.87Price Target Upside18.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Moderna News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ApprovalsNew cancer vaccine data shows a stronger Overall Survival (OS) trial in combination with PD1 compared to Keytruda alone, suggesting Moderna's treatment could be a significant advancement in cancer therapy.
Product Development And FundingModerna secures a funding agreement with Blackstone Life Sciences for up to $750 million to develop and commercialize the flu program, potentially reducing R&D costs and accelerating vaccine availability.
Vaccine EfficacyModerna's next-generation COVID-19 vaccine, mRNA-1283, demonstrates a higher immune response, indicating a potential improvement over existing vaccines, especially for populations over 65 years.
Bears Say
Financial PerformanceTop-line revenue growth has continued to decline, posing a challenging profit and loss backdrop as operating expenses remain high.
Future Growth ConcernsThere are concerns whether the company can achieve the $4B target in 2024 given that COVID revenue was mostly $3.7B in 2023.
Market CompetitionModerna's RSV vaccine faces an uphill battle as a third-to-market offering against two well capitalized pharma companies.
---
Ownership Overview
16.01% Insiders
19.41% Mutual Funds
21.54% Other Institutional Investors
43.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $62.55 and its highest was $144.93 in the past 12 months.
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is May 02, 2024 which is in 13 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Feb 22, 2024. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of -$0.987 by $1.537.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -$3.55.
How many shares outstanding does Moderna have?
Moderna has 382,879,600 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of $0.55 in its last earnings report, beating expectations of -$0.987. Following the earnings report the stock price went up 13.529%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Flagship Pioneering Inc.. It holds Moderna’s shares valued at 961M.
---
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$122.87 (18.39% Upside)
$122.87 (18.39% Upside)
Blogger Sentiment
Neutral
MRNA Sentiment 55%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 500.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.93%
12-Months-Change
Fundamentals
Return on Equity
-28.59%
Trailing 12-Months
Asset Growth
-29.37%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
MRNA Company Deck
---
MRNA Earnings Call
Q4 2024
0:00 / 0:00
---
MRNA Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
MRNA Stock 12 Months Forecast
Average Price Target
$122.87
▲(18.39% Upside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
24/25 ratings generated profit
1 Year Average Return
+269.55%
reiterated a buy rating 17 days ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +269.55% per trade.
---